CN102711798A - 刺激干细胞的药物组合物 - Google Patents

刺激干细胞的药物组合物 Download PDF

Info

Publication number
CN102711798A
CN102711798A CN201080053800XA CN201080053800A CN102711798A CN 102711798 A CN102711798 A CN 102711798A CN 201080053800X A CN201080053800X A CN 201080053800XA CN 201080053800 A CN201080053800 A CN 201080053800A CN 102711798 A CN102711798 A CN 102711798A
Authority
CN
China
Prior art keywords
pharmaceutical composition
pharmaceutical
fgf
growth factor
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080053800XA
Other languages
English (en)
Chinese (zh)
Inventor
R·戈登-贝瑞斯福特
V·高森
J·P·莱特尔德瓦尼萨
C·霍姆西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celyad Oncology SA
Original Assignee
Cardio3 Biosciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardio3 Biosciences SA filed Critical Cardio3 Biosciences SA
Publication of CN102711798A publication Critical patent/CN102711798A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201080053800XA 2009-12-02 2010-12-02 刺激干细胞的药物组合物 Pending CN102711798A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2009/066251 2009-12-02
EP2009066251 2009-12-02
PCT/EP2010/068700 WO2011067317A1 (en) 2009-12-02 2010-12-02 Pharmaceutical compositions for the stimulation of stem cells.

Publications (1)

Publication Number Publication Date
CN102711798A true CN102711798A (zh) 2012-10-03

Family

ID=42316097

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080053800XA Pending CN102711798A (zh) 2009-12-02 2010-12-02 刺激干细胞的药物组合物

Country Status (12)

Country Link
JP (1) JP2013512877A (enExample)
KR (1) KR20120099751A (enExample)
CN (1) CN102711798A (enExample)
AU (1) AU2010326633A1 (enExample)
BR (1) BR112012013164A2 (enExample)
CA (1) CA2781493A1 (enExample)
IL (1) IL219901A0 (enExample)
MX (1) MX2012005976A (enExample)
NZ (1) NZ599930A (enExample)
RU (1) RU2012120834A (enExample)
TW (1) TW201141510A (enExample)
WO (1) WO2011067317A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105079791A (zh) * 2015-09-18 2015-11-25 郑榆坤 一种刺激体内内源干细胞的组合物及其应用
CN106456676A (zh) * 2014-07-07 2017-02-22 米迪波斯特股份有限公司 经刺激的干细胞的培养基的毛发生长促进功能及其用途
CN107050428A (zh) * 2017-03-23 2017-08-18 温州医科大学 Fgf20药物及其对脑创伤的治疗应用
CN107648592A (zh) * 2017-11-13 2018-02-02 深圳市喆邦生物工程有限公司 趋化因子ccl4作为制备治疗骨折药物的应用
CN111621525A (zh) * 2020-06-18 2020-09-04 山东如戴生物科技有限公司 Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途
WO2021143243A1 (zh) * 2020-01-15 2021-07-22 重庆大学 IGF1和IGF1Ec24联合在制备促进组织修复与再生的药物中的应用
CN116836920A (zh) * 2023-08-21 2023-10-03 佛山市生物医学工程学会 一种无血清培养基及其制备间充质干细胞的方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2634576C1 (ru) * 2016-10-24 2017-10-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ стимуляции регенерации тканей
RU2686718C1 (ru) * 2018-03-12 2019-04-30 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro
KR102106710B1 (ko) 2018-10-11 2020-05-04 강원대학교산학협력단 인간 전분화능 줄기세포로부터 조혈모세포 및 대식세포 분화 증진 방법
US20240058389A1 (en) * 2020-03-17 2024-02-22 Hierabio Inc. Composition for preventing or treating ischemic diseases, comprising cardiac stem cells
KR20240131080A (ko) * 2023-02-23 2024-08-30 서울대학교산학협력단 배외내배엽 줄기세포의 배양용 배지 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081190A2 (en) * 2005-01-25 2006-08-03 Five Prime Therapeutics, Inc. Compositions and methods for treating cardiac conditions
US20080019944A1 (en) * 2006-07-24 2008-01-24 Mayo Foundation For Medical Education And Research Methods and Materials for Providing Cardiac Cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2532909T3 (es) * 2004-07-30 2015-04-01 Mayo Foundation For Medical Education And Research Tratamiento de tejido cardiovascular
US8481075B2 (en) * 2007-12-13 2013-07-09 Beijing Shengyiyao Science & Technology Development Co. Ltd. Preparation and application of biodegradable-material-made microsphere vascular embolus containing liposome-encapsulated cytokines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081190A2 (en) * 2005-01-25 2006-08-03 Five Prime Therapeutics, Inc. Compositions and methods for treating cardiac conditions
US20080019944A1 (en) * 2006-07-24 2008-01-24 Mayo Foundation For Medical Education And Research Methods and Materials for Providing Cardiac Cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ATTA BEHFAR ET AL.: "Cardicpoietic programming of embryonic stem cells for tumor-free heart repair", 《THE JOURNAL OF EXPERIMENTAL MEDCINE》, vol. 204, no. 2, 31 December 2007 (2007-12-31), pages 405 - 420, XP002462528, DOI: doi:10.1084/jem.20061916 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456676A (zh) * 2014-07-07 2017-02-22 米迪波斯特股份有限公司 经刺激的干细胞的培养基的毛发生长促进功能及其用途
CN106456676B (zh) * 2014-07-07 2021-07-23 米迪波斯特股份有限公司 经刺激的干细胞的培养基的毛发生长促进功能及其用途
CN105079791A (zh) * 2015-09-18 2015-11-25 郑榆坤 一种刺激体内内源干细胞的组合物及其应用
CN107050428A (zh) * 2017-03-23 2017-08-18 温州医科大学 Fgf20药物及其对脑创伤的治疗应用
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用
CN107648592A (zh) * 2017-11-13 2018-02-02 深圳市喆邦生物工程有限公司 趋化因子ccl4作为制备治疗骨折药物的应用
WO2021143243A1 (zh) * 2020-01-15 2021-07-22 重庆大学 IGF1和IGF1Ec24联合在制备促进组织修复与再生的药物中的应用
CN111621525A (zh) * 2020-06-18 2020-09-04 山东如戴生物科技有限公司 Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途
CN116836920A (zh) * 2023-08-21 2023-10-03 佛山市生物医学工程学会 一种无血清培养基及其制备间充质干细胞的方法
CN116836920B (zh) * 2023-08-21 2024-05-24 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 一种无血清培养基及其制备间充质干细胞的方法

Also Published As

Publication number Publication date
AU2010326633A1 (en) 2012-05-31
IL219901A0 (en) 2012-07-31
TW201141510A (en) 2011-12-01
MX2012005976A (es) 2012-06-25
CA2781493A1 (en) 2011-06-09
WO2011067317A1 (en) 2011-06-09
JP2013512877A (ja) 2013-04-18
BR112012013164A2 (pt) 2016-03-01
NZ599930A (en) 2014-04-30
KR20120099751A (ko) 2012-09-11
RU2012120834A (ru) 2014-01-20

Similar Documents

Publication Publication Date Title
EP2506867B1 (en) Pharmaceutical compositions for the stimulation of stem cells.
CN102711798A (zh) 刺激干细胞的药物组合物
Song et al. Regeneration of chronic myocardial infarction by injectable hydrogels containing stem cell homing factor SDF-1 and angiogenic peptide Ac-SDKP
Rufaihah et al. Dual delivery of VEGF and ANG-1 in ischemic hearts using an injectable hydrogel
Azarnoush et al. Enhancement of the functional benefits of skeletal myoblast transplantation by means of coadministration of hypoxia-inducible factor 1α
CN102170868A (zh) 包含介于10和20微米之间直径的微球的胃肠外给药组合物
Sanganalmath et al. Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond
CN111093769A (zh) 来源于皮质骨干细胞的外来体可以增强心脏损伤后的心脏功能
Hsiao et al. Ischemic preconditioning for cell-based therapy and tissue engineering
US20130095060A1 (en) Pharmaceutical composition for promoting arteriogenesis, and preparation method and applications for the same
JP2013512877A5 (enExample)
JP2023105066A (ja) 組織治癒剤
US20080102059A1 (en) Treatment for arthritis
Cho et al. Enhancement of angiogenic efficacy of human cord blood cell transplantation
Fukuda et al. Angiogenic strategy for human ischemic heart disease: brief overview
JP5205668B2 (ja) 可動化活性を有する調製物
Kanemitsu et al. Insulin-like growth factor-1 enhances the efficacy of myoblast transplantation with its multiple functions in the chronic myocardial infarction rat model
Waksman et al. Bone marrow and bone marrow derived mononuclear stem cells therapy for the chronically ischemic myocardium
Zhang et al. Topical delivery of gel-in-oil emulsion cocktail with growth factors for the treatment of diabetic pressure ulcers
US20030044396A1 (en) Methods for treating diseases and increasing longevity
US20200009226A1 (en) Compositions and Methods for Treating Stroke
JP4790195B2 (ja) 組織再生剤
WO2014027361A1 (en) A growth factor concentrate for treating periorbital hyperpigmentation
KR20250166096A (ko) 건조 안 질환치료용 거핵구 유도체
Širmenis et al. Recovery of infarcted myocardium in an in vivo experiment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121003